Latest News
Flerie portfolio company Bonsai Biotherapeutics secures clinical trial approval for TOL2 in myasthenia gravis
26 June 2026 - Life science investor Flerie AB (STO:FLERIE) announced on Friday that its portfolio company Bonsai Biotherapeutics has received full approval of its clinical trial application for TOL2 in AChR antibody-positive generalised myasthenia g...
bioMérieux files FDA application for rapid vaginitis diagnostic panel
26 June 2026 - French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Friday that it has submitted a Dual 510(k)/CLIA Waiver application to the US Food and Drug Administration (FDA) for the BIOFIRE SPOTFIRE Vaginitis (VG) Pane...
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
26 June 2026 - Clinical-stage biotechnology company MaaT Pharma (Euronext Paris:MAAT) said on Friday that it will request a re-examination of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) negative opinion ...
Racura Oncology doses first patient in Phase 1 lung cancer trial
26 June 2026 - Australian-based clinical-stage biopharmaceutical company Racura Oncology Limited (ASX:RAC) announced on Thursday that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial evaluating RC220 in combinatio...
NeuroSense reports Phase 2 proof-of-concept study results for PrimeC in Alzheimer's Disease
26 June 2026 - Late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) on Thursday reported positive biomarker findings from its Phase 2 randomised, double-blind, placebo-controlled proof-of-concept RoAD study (NST-AD-001)...